Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways.
Pharmazie
; 70(2): 117-22, 2015 Feb.
Article
en En
| MEDLINE
| ID: mdl-25997252
Metformin is usually used for the treatment of type 2 diabetes. Recently, many studies suggest that metformin and vitamin D have broad-spectrum antitumor activities. Our aim in this research was to study the effects of vitamin D3 combined with metformin on the apoptosis induction and its mechanisms in the human breast cancer cell line MDA-MB-231. Cell proliferation was measured by methylthiazol tetrazolium (MTT) assay. The morphology of cell apoptosis was observed after Hoechst 33342 staining. Here we show that vitamin D3 280 µg/ml or vitamin D3 300 µg/ml or vitamin D3 320 µg/ml seperately combined with metformin 15000 µg/ml exhibited synergistic effects on cell proliferation and apoptosis. The underlying anti-tumor mechanisms may involve m-TOR related pathways, which are related to activating expression of cleaved caspase-3, Bax and p-AMPK, as well as inhibiting expressions of p-Bcl-2, c-Myc, p-IGF-IR, p-mTOR, p-P70S6K, p-S6.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vitaminas
/
Neoplasias de la Mama
/
Colecalciferol
/
Serina-Treonina Quinasas TOR
/
Hipoglucemiantes
/
Metformina
Límite:
Female
/
Humans
Idioma:
En
Revista:
Pharmazie
Asunto de la revista:
FARMACIA
Año:
2015
Tipo del documento:
Article
Pais de publicación:
Alemania